Xenon Pharmaceuticals (NASDAQ:XENE) Posts Earnings Results, Misses Expectations By $0.11 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) issued its earnings results on Thursday. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11), Zacks reports. During the same period in the previous year, the firm earned ($0.84) EPS.

Xenon Pharmaceuticals Trading Up 0.8%

Shares of XENE opened at $44.92 on Friday. The firm has a market cap of $3.47 billion, a P/E ratio of -11.55 and a beta of 0.96. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $46.60. The stock’s 50 day moving average is $42.51 and its two-hundred day moving average is $40.94.

Wall Street Analysts Forecast Growth

XENE has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Friday, January 9th. Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Wells Fargo & Company upped their target price on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the stock an “overweight” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. lifted their price target on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Finally, Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $55.17.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer owned 6,000 shares in the company, valued at $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 65,205 shares of company stock worth $2,919,762. Corporate insiders own 4.07% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Holocene Advisors LP purchased a new position in Xenon Pharmaceuticals during the second quarter valued at $56,637,000. Wellington Management Group LLP raised its position in shares of Xenon Pharmaceuticals by 66.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Xenon Pharmaceuticals by 1,968.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock valued at $38,650,000 after buying an additional 820,608 shares in the last quarter. Vestal Point Capital LP lifted its stake in Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after buying an additional 700,000 shares in the last quarter. Finally, Commodore Capital LP boosted its holdings in Xenon Pharmaceuticals by 30.1% in the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock worth $94,682,000 after buying an additional 700,000 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.